Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment

• Hong Chen,
• Padmanee Sharma,
• James P Allison,
• Sumit K Subudhi,
• Sonali Jindal,
• Sreyashi Basu,
• Bilal A Siddiqui,
• Paul G Corn,
• Ana M Aparicio,
• Shalini S Yadav,
• Rebecca S S Tidwell,
• Ashwin Varma,
• Christopher J Logothetis

Affiliations

Hong Chen

The Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Padmanee Sharma

Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

James P Allison

The Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Sumit K Subudhi

Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Sonali Jindal

The Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Sreyashi Basu

The Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Bilal A Siddiqui

Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Paul G Corn

Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Ana M Aparicio

Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Shalini S Yadav

The Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Rebecca S S Tidwell

Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Ashwin Varma

Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Christopher J Logothetis

Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA